ArrayPatch ltd

ArrayPatch Ltd is a BioTech spinout https://array-patch.com/ leveraging its proprietary, award winning DerMap™ dissolving microneedle patch technology to develop new treatments across a number of therapeutic areas which are more efficacious and safer. DerMap™ is a pain free microneedle patch comprising microscopic needles which, uniquely, are made from the drug being delivered. On application of the patch, the microneedles penetrate the outer layer of skin, dissolve and release medication to the target site. 

· Company History: Incorporated March 2024 secured exclusive license to DerMap™ technology in June 2024. Assembled experienced team and identified an attractive business model. The executive team's combined skills in industry with proven track record in microneedle manufacturing, regulatory approval, product launch, fundraising and business development positions the company for success.

· Mission Statement: Levering the DerMap™ delivery technology to provide a superior treatment options for healthcare professionals and their patients.

· Technology: In the last six years, more than €1.3M was invested in the DerMap™ technology prior to spin-out to ArrayPatch. The technology is the first of its kind of dissolving microneedle patch technology, whereby the microneedles are made entirely of the medicine (drug) being delivered (with no polymers), allowing for greater efficacy versus other approaches.

· Location: The company headquarters is based in Cork, Ireland.

· First product and target market: The first product being developed, ITZ-DerMap™, is for the targeted treatment of nail fungal infection, a global market with over $6B and where significant unmet medical need remains. We have completed proof of concept, all preclinical data is ready, and our clinical roadmap is in place. Clinical trials are set to begin in Q1-2026. Initially the product will be launched in the EU with a US launch and other markets close behind. The company estimates capturing a market share of up to 10% of topical treatments, while also penetrating oral and OTC markets, yielding potential annual revenues of €300M.

· Pipeline: The pipeline also includes applications in skin cancer, small peptide, hormone replacement therapy and migraine, markets worth a combined $70B. As DerMap™ products involve the delivery of proven compounds the time to market, development cost and risk is significantly reduced compared with conventional drug development. Partnering of these programs represents an opportunity to generate further revenue.  

· Business Model: ArrayPatch will develop and commercialise its DerMap™ products through strategic partnerships with industry partners. These partners, including large pharmaceutical companies, will have strong presence and capabilities in the product target markets. This partnership model will facilitate accelerated product development, reduce costs and risk and ensure success in the market of its DerMap™ products. ArrayPatch has active discussions on going with a number of such strategic partners.

· Financing strategy: The company is currently raising its inaugural financing round, a €3M seed round. This capital will be used to scale up manufacturing of the ITZ-DerMap™ product and advance it through value enhancing, de-risking clinical milestones, notably a Phase 1 trial in 12 volunteers designed to show safety, along with collection of well designed biomarkers to provide initial evidence of efficacy and action. This results from this initial trial will likely attract significant interest from larger pharmaceutical companies and may offer an early exit opportunity for investors in 2027.

Thereafter, it is estimated that a further €12.5M will be required in 2027 to fund the ITZ-DerMap™ product through a larger Phase 3 clinical trial thus paving the way for commercialisation in the marketplace in 2029/30. These funds may be secured from further equity investment or through strategic collaborations with larger strategic partners.